Montpellier, April 24, 2025 – The Léon Bérard Center (CLB), a cancer treatment center in Lyon, has just installed Epione®, the platform developed by Quantum Surgical that enables early and curative treatment of tumors. The first patients have already been treated. CLB becomes the sixth site in France to offer this minimally invasive treatment, which destroys abdominal and lung tumors by inserting a needle through the skin.
Specializing in robotics and artificial intelligence, Quantum Surgical develops the Epione robotic platform, which enables physicians to perform safe and effective percutaneous tumor ablations. This minimally invasive treatment is an alternative to surgery, involving the insertion of one or more needles through the skin to reach and destroy the tumor.
Epione has already been used to treat 875 patients worldwide and is now available at Léon Bérard Center in Lyon.
“The adoption of the Epione robot marks a major advancement for our department and our patients. Thanks to this cutting-edge technology, we can perform minimally invasive procedures with unmatched precision, thereby reducing risks and significantly improving patient care. This innovation strengthens our commitment to providing the highest quality of care in interventional radiology,” explains Dr. Amine Bouhamama, interventional radiologist at the Léon Bérard Center.
“At the Léon Bérard Center, we are deeply committed to offering our patients ever more advanced and compassionate care. We are therefore proud to integrate the innovation represented by Epione into our therapeutic options, providing our patients with procedures that are more precise, less invasive, and safer,” says Professor Jean-Yves Blay, General Director of the Léon Bérard Center.
“We are delighted with this new installation at the Léon Bérard Center. The deployment of a second Epione just weeks after the one at Toulouse University Hospital is a true validation of the benefits our platform offers. The entire Quantum Surgical team is thrilled that more patients can now benefit from our technology to treat their tumors,” says Bertin Nahum, President and Co-founder of Quantum Surgical.
Epione is CE-marked in Europe for abdominal and lung tumors and FDA-approved in the United States for abdominal tumors. Epione is available in about 20 hospitals worldwide including at Baptist Health South Florida in Miami, Florida and Rush University System Health in Chicago, Illinois.
About Quantum Surgical
Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 130 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.
Its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.
Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.
More information: www.quantumsurgical.com
Press contact Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33 (0)6 32 55 85 48
About the Léon Bérard Center (CLB)
The Léon Bérard Center is a member of the Unicancer network, which brings together 18 French Cancer Centers and one affiliated institution. It is recognized as a regional, national, and international center of excellence in oncology. Located in Lyon, one of France’s major cities, the CLB fulfills a threefold mission of care, research, and education, with a constant focus on improving the quality and accessibility of cancer care.
All diagnostic tests, treatments, and patient follow-up during and after illness are provided on a single site. The Center receives more than 45,000 patients each year for hospital stays, consultations, or examinations, and diagnoses over 6,000 new tumors annually.
The CLB has over 2,200 staff members, including 280 physicians, 600 researchers, and 800 caregivers. One of the Center’s strengths is its seamless integration of care and research. On-site, doctors and researchers work closely together to shorten the time between laboratory discoveries and their application to patient care. As a result, more than 2,000 patients are enrolled each year in one of the 300 open clinical trials.
Press contact Léon Bérard Center
Julie Colomb
julie.colomb@lyon.unicancer.fr
Tél.: +33 (0)4 69 85 61 85
